HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane
Paula Raffin Pohlmann, Deena Mary Atieh Graham, Tianmin Wu et al. · Breast Cancer Research and Treatment · 2022
PURPOSE: To assess whether crofelemer would prevent chemotherapy-induced diarrhea (CID) diarrhea in patients with HER2-positive, any-stage breast cancer receiving trastuzumab (H), pertuzumab (P), and a taxane (T; docetaxel or paclitaxel), with/without carboplatin (C; always combined with docetaxel rather than paclitaxel). METHODS: Patients scheduled to receive ≥ 3 consecutive TCHP/THP cycles were randomized to crofelemer 125 mg orally twice daily during chemotherapy cycles 1 and 2 or no scheduled prophylactic medication (control). All received standard breakthrough antidiarrheal medication (BTAD) as needed. The primary endpoint was incidence of any-grade CID for ≥ 2 consecutive days. Secondary endpoints were incidence of all-grade and grade 3/4 CID by cycle/stratum; time to onset and duration of CID; stool consistency; use of BTAD; and quality of life (Functional Assessment of Chronic Illness Therapy for Patients With Diarrhea [FACIT-D] score). RESULTS: Fifty-one patients were randomized to crofelemer (n = 26) or control (n = 25). There was no statistically significant difference between arms for the primary endpoint; however, incidence of grade ≥ 2 CID was reduced with crofelemer vs control (19.2% vs 24.0% in cycle 1; 8.0% vs 39.1%, in cycle 2). Patients receiving crofelemer were 1.8 times more likely to see their diarrhea resolved and had less frequent watery diarrhea. CONCLUSION: Despite the choice of primary endpoint being insensitive, crofelemer reduced the incidence and severity of CID in patients with HER2-positive breast cancer receiving P-based therapy. These data are supportive of further testing of crofelemer in CID. TRIAL REGISTRATION: Clinicaltrials.gov, NCT02910219, prospectively registered September 21, 2016.
Cited by 11 works. doi:10.1007/s10549-022-06743-9 Open-access PDF
Authors
- Paula Raffin Pohlmann
- Deena Mary Atieh Graham
- Tianmin Wu
- Yvonne Lynn Ottaviano
- Mahsa Mohebtash
- Shweta Kurian
- Donna M. McNamara
- Filipa C. Lynce
- Robert D. Warren
- Asma Ali Dilawari
- Suman Rao
- Candace Bavette Mainor
- Nicole Swanson
- Ming Tony Tan
- Claudine J. Isaacs
- Sandra M. Swain
References
- Stool Form Scale as a Useful Guide to Intestinal Transit Time
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
- Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate.
- Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer
- Recommended Guidelines for the Treatment of Cancer Treatment-Induced Diarrhea
- Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients